Natera (NASDAQ:NTRA) Issues Quarterly Earnings Results

Natera (NASDAQ:NTRA) posted its quarterly earnings results on Tuesday. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.31, Briefing.com reports. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The company’s revenue was up 63.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.95) earnings per share. Natera updated its FY 2024 guidance to EPS.

Natera Stock Performance

Shares of NTRA opened at $135.12 on Wednesday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The stock has a market cap of $16.71 billion, a P/E ratio of -55.15 and a beta of 1.53. The business’s 50 day moving average price is $125.09 and its 200-day moving average price is $114.52. Natera has a 52 week low of $46.96 and a 52 week high of $140.00.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NTRA. Stephens restated an “overweight” rating and set a $125.00 target price on shares of Natera in a report on Friday, August 9th. Robert W. Baird raised their target price on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Morgan Stanley raised their price target on shares of Natera from $125.00 to $132.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group upped their price objective on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.13.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total value of $663,874.53. Following the sale, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at approximately $23,866,426.10. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Steven Leonard Chapman sold 5,583 shares of the stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53. Following the transaction, the chief executive officer now directly owns 200,710 shares of the company’s stock, valued at $23,866,426.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction on Thursday, October 31st. The stock was sold at an average price of $126.45, for a total value of $235,955.70. Following the completion of the transaction, the chief financial officer now owns 68,851 shares in the company, valued at approximately $8,706,208.95. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 47,464 shares of company stock worth $5,849,977. 7.60% of the stock is owned by insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.